Image of oligodendrocytes after NFIX is deleted
When NFIX is eliminated and neural stem cells are allowed to differentiate, there is an increase in the fraction of oligodendrocytes (white), with no obvious change in astrocytes (green) or neurons (red). Cell nuclei are shown in blue. (Credit: Bo Zhou and Richard Gonostajski)
A new way to generate oligodendrocytes has potential to enhance treatments for brain injury, MS, Alzheimer’s and more
By Ellen Goldbaum
“This is of interest because producing more oligodendrocytes could help prevent the damage to neurons that occurs in MS and other demyelinating diseases, such as Krabbe’s Disease.”
Richard Gronostajski, PhD, Professor
Department of Biochemistry
That’s the conclusion of University at Buffalo scientists after deleting from the adult brain a protein necessary for early development. They found that this deletion actually fosters the growth of cells that generate myelin, the important protective coating neurons need to function.
The research on lab animals, published in Stem Cells and Development on July 28, provides new insight into how critical brain cells are generated. The finding may lead to improved treatments for brain injury, demyelinating diseases, certain developmental diseases and brain tumors.
The UB researchers studied Nuclear Factor I X (NFIX), a transcription factor – a protein that turns genes on and off.
NFIX is required for normal development of the early brain and it’s known that losing NFIX before birth results in a number of rare human diseases, characterized by severe developmental and physiological defects.
However, the new study shows that the loss of NFIX is necessary at a certain point in order for some brain cells to develop normally.
“This paper is about the increase in oligodendrocytes, the myelin-making cells, that we discovered when we deleted NFIX from adult neural stem cells,” explained lead author Richard M. Gronostajski, PhD, professor in the UB Department of Biochemistry. “This is of interest because producing more oligodendrocytes could help prevent the damage to neurons that occurs in MS and other demyelinating diseases, such as Krabbe’s Disease.” He directs the Genetics, Genomics and Bioinformatics Graduate program in the UB School of Medicine and Biomedical Sciences and UB’s Western New York Stem Cell Culture and Analysis Center (WNYSTEM).
Gronostajski’s lab is at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences and he is also a professor at Roswell Park Cancer Institute.
Thirty years ago, while working in a lab at Albert Einstein College of Medicine, he contributed to the discovery of NFI proteins. His new research demonstrates how complex a role NFIX and other related transcription factors play in development.
He explained that oligodendrocytes surround neurons, which transmit electrical signals in the brain, protecting them from damage and speeding the transmission of those signals.
The research shows that as neural stem cells differentiate into oligodendrocytes, the expression of NFIX decreases, apparently an essential step in the normal formation of the myelin-making cells.
“In terms of a treatment, this could lead to the development of a small molecule that could be used to shut off NFIX activity in MS patients, thus promoting the growth of more oligodendrocytes,” explained Gronostajski.
This study and previous ones have found that loss of NFIX could also increase the growth of adult neural stem cells, which, in turn, generate new neurons in adult animals.
“This could also help us find ways to stimulate new neuron production in diseases where neurons die, such as in Alzheimer’s and Parkinson’s diseases and in spinal cord injury,” he said.
The researchers’ next step is to learn which genes are regulated by NFIX, and the best way to promote this increase in both oligodendrocytes and neural stem cells.
UB co-authors on the paper are Christine E. Campbell, research assistant professor Jason Osinski, research technician and Bo Zhou, graduate student, all in the Department of Biochemistry, Fraser Sim, PhD, associate professor in the Department of Pharmacology and Toxicology. Other co-authors are Juan L. Mateo of the University of Heidelberg; Francois Guillemot and Ben Martynoga of the Francis Crick Institute in London and Michael Piper of the University of Queensland.
The work was funded by NYSTEM contracts C026429 and C026714, National Health and Medical Research Council project grants and the Australian Research Council Future Fellowship.
Media Contact Information
News Content Manager